|Chemical and physical data|
|Molar mass||597.760 g·mol−1|
|3D model (JSmol)|
Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|